NVSEF (Novartis AG) YoY EPS Growth: -9.34% (As of Mar. 2026)


NVSEF Novartis AG NVSEF
80 GF Score
Price $150.61
GF Value $124.90
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Novartis AG YoY EPS Growth?

Novartis AG NVSEF +0.65% 80 YoY EPS Growth is -9.34% as of Mar. 2026. GuruFocus rates NVSEF with a GF Score™ of 80/100 and a GF Value™ of $124.90 (Modestly Overvalued). The stock has 6 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Novartis AG's YoY EPS Growth for the quarter that ended in Mar. 2026 was -9.34%.

Novartis AG's Earnings per Share (Diluted) for the three months ended in Mar. 2026 was $1.65.

Novartis AG YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Novartis AG's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG YoY EPS Growth Chart

Novartis AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 201.99 -70.18 123.97 -17.32 21.81

Novartis AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.93 29.56 28.66 -11.35 -9.34
NVSEF
80GF Score
Novartis AG NVSEF
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novartis AG YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Novartis AG's YoY EPS Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EPS Growth (A: Dec. 2025 )
=(Earnings per Share (Diluted) (A: Dec. 2025 )-Earnings per Share (Diluted) (A: Dec. 2024 ))/ | Earnings per Share (Diluted) (A: Dec. 2024 ) |
=(7.15-5.87)/ | 5.87 |
=21.81 %

Novartis AG's YoY EPS Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EPS Growth (Q: Mar. 2026 )
=(Earnings per Share (Diluted) (Q: Mar. 2026 )-Earnings per Share (Diluted) (Q: Mar. 2025 )) / | Earnings per Share (Diluted) (Q: Mar. 2025 )) |
=(1.65-1.82)/ | 1.82 |
=-9.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of -9.34% mean?
Novartis AG (NVSEF) has a YoY EPS Growth of -9.34% as of Mar. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Novartis AG and its competitors.
Is Novartis AG's YoY EPS Growth too high?
Novartis AG's current YoY EPS Growth is -9.34%. Overall, Novartis AG has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novartis AG's YoY EPS Growth compare to LLY and JNJ?
Novartis AG's YoY EPS Growth of -9.34% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Drug Manufacturers company?
A good YoY EPS Growth depends on the Drug Manufacturers industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Novartis AG and its competitors. Novartis AG's current YoY EPS Growth is -9.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis AG stock overvalued right now?
Based on GuruFocus' analysis, Novartis AG (NVSEF) is currently considered Modestly Overvalued. The stock's GF Value™ is $124.90, compared to a current price of $150.61 — trading 20.6% above its estimated fair value. The current YoY EPS Growth is -9.34%. Novartis AG's overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Novartis AG (NVSEF), the current YoY EPS Growth is -9.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novartis AG (NVSEF) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued. The current stock price of $150.61 is trading 20.6% above its estimated GF Value™ of $124.90. GuruFocus considers Novartis AG to be Modestly Overvalued.

Key valuation signals for NVSEF:

  • YoY EPS Growth: -9.34%
  • GF Value™: $124.90 vs. price of $150.61 (20.6% above fair value)
  • GF Score™: 80/100 with 6 warning signs

No single metric tells the full story. See the NVSEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novartis AG Business Description

Address Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
80GF Score

Get the complete analysis for NVSEF

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$150.61
Price
$124.90
GF Value